The trademark ENLAZA THERAPEUTICS was filed by Enlaza Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on July 9, 2023, and received one opposition filed on October 9, 2023 by CONNECTA THERAPEUTICS, S.L. on Likelihood of confusion. the opponent was represented by ABG INTELLECTUAL PROPERTY and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued October 9, 2023
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:
Chemical products for use in industry and science
Reagents for use in scientific apparatus for chemical or biological analysis
Reagents for medical research
Antibody reagents for scientific purposes
In-vivo diagnostic reagents for scientific or research use
Enzymes for scientific use
Cell culture media for use in scientific research
Active chemical ingredients for use in the manufacture of anti-cancer drugs
Laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors
Antibodies for research use.
The mark was filed in class 5 with following description of goods:
Pharmaceutical products, preparations, and substances for the treatment of cancer
Cancer therapeutics, namely, anti-cancer preparations
Novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors
Biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer
Pharmaceutical products consisting of covalent protein biologics
Pharmaceutical products, namely, covalent protein drugs
Pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics
Pharmaceutical products consisting of covalent protein drugs
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals.
The mark was filed in class 42 with following description of goods:
Research and development in the field of covalent protein biologics
Medical and scientific research in the field of cancer treatment and diagnosis
Pharmaceutical research and development
Research and development of pharmaceuticals and biologicals in the field of cancer therapeutics
Research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs
Research and development for the purpose of selective covalent modification of proteins
Research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer
Research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors
Conducting clinical trials for others in the field of cancer therapeutics
Biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, and analysis
Research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies
Research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies.